Phibro Animal Health Corp
NASDAQ:PAHC

Watchlist Manager
Phibro Animal Health Corp Logo
Phibro Animal Health Corp
NASDAQ:PAHC
Watchlist
Price: 39.16 USD -3.95% Market Closed
Market Cap: 1.6B USD
Section:
 

Relative Value

The Relative Value of one PAHC stock under the Base Case scenario is 55.05 USD. Compared to the current market price of 39.16 USD, Phibro Animal Health Corp is Undervalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PAHC Relative Value
Base Case
55.05 USD
Undervaluation 29%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
6
vs Industry
74
Median 3Y
0.7
Median 5Y
0.8
Industry
2.6
Forward
1.1
More Details
23.4
P/E
P/E
Price to Earnings
23.4
vs History
31
vs Industry
9
Median 3Y
24.4
Median 5Y
20.5
Industry
21.7
Forward
14
More Details
20.6
P/OCF
P/OCF
Price to OCF
20.6
vs History
19
vs Industry
27
Median 3Y
10.8
Median 5Y
14.3
Industry
16.6
More Details
5.2
P/FCFE
P/FCFE
Price to FCFE
5.2
vs History
74
vs Industry
35
Median 3Y
12.4
Median 5Y
22.8
Industry
22.5
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
3
vs Industry
21
Median 3Y
2.6
Median 5Y
3.1
Industry
2.3
More Details
1.6
EV/S
EV/S
Enterprise Value to Sales
1.6
vs History
6
vs Industry
63
Median 3Y
1
Median 5Y
1.2
Industry
2.9
Forward
1.5
More Details
5
EV/GP
EV/GP
Enterprise Value to Gross Profit
5
vs History
4
vs Industry
45
Median 3Y
3.4
Median 5Y
3.7
Industry
5.5
More Details
10.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.2
vs History
26
vs Industry
31
Median 3Y
9.4
Median 5Y
9.5
Industry
13.1
Forward
9.3
More Details
13.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.2
vs History
55
vs Industry
29
Median 3Y
13.7
Median 5Y
13.7
Industry
16.6
Forward
11.5
More Details
29
EV/OCF
EV/OCF
Enterprise Value to OCF
29
vs History
19
vs Industry
16
Median 3Y
17.5
Median 5Y
21.5
Industry
15.8
More Details
64.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
64.9
vs History
28
vs Industry
5
Median 3Y
26.2
Median 5Y
33.1
Industry
19.1
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
6
vs Industry
46
Median 3Y
1.3
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

PAHC Competitors Multiples
Phibro Animal Health Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Phibro Animal Health Corp
NASDAQ:PAHC
1.6B USD 1.1 23.4 10.2 13.2
US
Eli Lilly and Co
NYSE:LLY
955.6B USD 16.1 51.9 34.9 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.9B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
247.6B CHF 4 26.3 11.3 13.1
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.8 29.9 108.2 158.4
CH
Novartis AG
SIX:NOVN
205.5B CHF 4.6 17.7 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
248B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
US
Phibro Animal Health Corp
NASDAQ:PAHC
Average P/E: 23.3
23.4
42%
0.6
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.3
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Phibro Animal Health Corp
NASDAQ:PAHC
Average EV/EBITDA: 398.7
10.2
14%
0.7
US
Eli Lilly and Co
NYSE:LLY
34.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.3
4%
2.8
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Phibro Animal Health Corp
NASDAQ:PAHC
Average EV/EBIT: 1 708.8
13.2
17%
0.8
US
Eli Lilly and Co
NYSE:LLY
37.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3

See Also

Summary
PAHC intrinsic value, competitors valuation, and company profile.
DCF Valuation
PAHC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PAHC stock valuation using valuation multiples.
Wall Street Estimates
PAHC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PAHC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.